LONDON, February 1, 2018 /PRNewswire/ --
Report Details
Do you need definitive Orphan Drugs market data? Succinct Orphan Drugs market analysis? Technological insight? Actionable business recommendations?
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Read on to discover how this definitive report can transform your own research and save you time.
The Global Orphan Drugs market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level studies have led to the discovery of new targets for therapy and producing disease modifying drugs.
Report highlights
149 quantitative tables, charts, and graphs across 173 pages
Global Orphan Drugs market outlook and analysis from 2018-2028
Global Orphan Drugs submarket forecasts and analysis from 2018-2028 Oncology Alimentary Tract & Metabolism Hormonal Disorders & Haematology Neuroscience Respiratory Cardiovascular Nephrology
Key National Orphan Drugs market forecasts 2018-2028 US forecast 2018-2028 Germany forecast 2018-2028 UK forecast 2018-2028 France forecast 2018-2028 Italy forecast 2018-2028 Spain forecast 2018-2028 Japan forecast 2018-2028 Singapore forecast 2018-2028 South Korea forecast 2018-2028 Brazil forecast 2018-2028 Russia forecast 2018-2028 China forecast 2018-2028 Brazil forecast 2018-2028
Key questions answered What does the future hold for the Pharmaceutical industry with regards to Orphan Drugs Where should you target your business strategy? Which applications should you focus upon? Which disruptive technologies should you invest in? Which companies should you form strategic alliances with? Which company is likely to success and why? What business models should you adopt? What industry trends should you be aware of?
Target audience Leading Pharmaceutical companies Suppliers Contractors Technologists R&D staff Consultants Analysts CEO's CIO's COO's Business development managers Investors Governments Agencies Banks
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2113/Orphan-Drugs-Market-Report-2018-2028
Companies Mentioned in the Report
Acorda Therapeutics
ABBVIE INC
AbbVie Ltd
Actelion Pharmaceuticals
Advanced Accelerator Applications
Aegerion Pharmaceuticals
Alexion
Amgen
Amicus Therapeutics UK Ltd
Arbor Pharmaceuticals LLC
AstraZeneca
AVEDRO INC
Baxalta Innovations GmbH
Baxter International
Bayer
Bio Products Laboratory Ltd
Biogen Idec Ltd
Biomarin
Bioprojet Pharma
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Quibb
Celgene
Clovis Oncology Inc
CSL Behring GmbH
EISAI INC
Eli Lilly And Company
Eli Lilly Nederland B.V.
Elusys Therapeutics, Inc
Genentech, Inc
GlaxoSmithKline Trading Services Limited
Intercept Pharmaceuticals Inc
Janssen Pharmaceuticals Inc
Janssen-Cilag International N.V.
Jazz Pharmaceuticals Inc
Lundbeck Llc
Merck
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
MolMed SpA
Navidea Biopharmaceuticals
Nova Laboratories Limited
Novarits
Novatech SA
Novo Nordisk Inc.
NX Development Corporation
Onyx Therapeutics Inc.
Otsuka Pharmaceutical
Pfizer
Pharmacyclics
Pharming Group
Pierre Fabre Dermatologie
Provepharm
Provepharm
PTC Therapeutics
Rare Disease Therapeutics
Retrophin
Roche
Sarepta Therapeutics
Seattle Genetics
Shire-NPS Pharmaceuticals
Silvergate Pharmaceuticals
Spectrum Pharmaceuticals
Strongbridge
Swedish Orphan Biovitrum AB
Takeda Pharma
Tesaro
Teva Pharmaceuticals
United Therapeutics Corporation
Vanda Pharmaceuticals
Veloxis Pharmaceuticals
Vertex Pharmaceuticals
Wellstat Therapeutics
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies
Advertisement
Report Details
Do you need definitive Orphan Drugs market data? Succinct Orphan Drugs market analysis? Technological insight? Actionable business recommendations?
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Read on to discover how this definitive report can transform your own research and save you time.
The Global Orphan Drugs market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level studies have led to the discovery of new targets for therapy and producing disease modifying drugs.
Report highlights
149 quantitative tables, charts, and graphs across 173 pages
Global Orphan Drugs market outlook and analysis from 2018-2028
Global Orphan Drugs submarket forecasts and analysis from 2018-2028 Oncology Alimentary Tract & Metabolism Hormonal Disorders & Haematology Neuroscience Respiratory Cardiovascular Nephrology
Key National Orphan Drugs market forecasts 2018-2028 US forecast 2018-2028 Germany forecast 2018-2028 UK forecast 2018-2028 France forecast 2018-2028 Italy forecast 2018-2028 Spain forecast 2018-2028 Japan forecast 2018-2028 Singapore forecast 2018-2028 South Korea forecast 2018-2028 Brazil forecast 2018-2028 Russia forecast 2018-2028 China forecast 2018-2028 Brazil forecast 2018-2028
Key questions answered What does the future hold for the Pharmaceutical industry with regards to Orphan Drugs Where should you target your business strategy? Which applications should you focus upon? Which disruptive technologies should you invest in? Which companies should you form strategic alliances with? Which company is likely to success and why? What business models should you adopt? What industry trends should you be aware of?
Target audience Leading Pharmaceutical companies Suppliers Contractors Technologists R&D staff Consultants Analysts CEO's CIO's COO's Business development managers Investors Governments Agencies Banks
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2113/Orphan-Drugs-Market-Report-2018-2028
Companies Mentioned in the Report
Acorda Therapeutics
ABBVIE INC
AbbVie Ltd
Actelion Pharmaceuticals
Advanced Accelerator Applications
Aegerion Pharmaceuticals
Alexion
Amgen
Amicus Therapeutics UK Ltd
Arbor Pharmaceuticals LLC
AstraZeneca
AVEDRO INC
Baxalta Innovations GmbH
Baxter International
Bayer
Bio Products Laboratory Ltd
Biogen Idec Ltd
Biomarin
Bioprojet Pharma
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Quibb
Celgene
Clovis Oncology Inc
CSL Behring GmbH
EISAI INC
Eli Lilly And Company
Eli Lilly Nederland B.V.
Elusys Therapeutics, Inc
Genentech, Inc
GlaxoSmithKline Trading Services Limited
Intercept Pharmaceuticals Inc
Janssen Pharmaceuticals Inc
Janssen-Cilag International N.V.
Jazz Pharmaceuticals Inc
Lundbeck Llc
Merck
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
MolMed SpA
Navidea Biopharmaceuticals
Nova Laboratories Limited
Novarits
Novatech SA
Novo Nordisk Inc.
NX Development Corporation
Onyx Therapeutics Inc.
Otsuka Pharmaceutical
Pfizer
Pharmacyclics
Pharming Group
Pierre Fabre Dermatologie
Provepharm
Provepharm
PTC Therapeutics
Rare Disease Therapeutics
Retrophin
Roche
Sarepta Therapeutics
Seattle Genetics
Shire-NPS Pharmaceuticals
Silvergate Pharmaceuticals
Spectrum Pharmaceuticals
Strongbridge
Swedish Orphan Biovitrum AB
Takeda Pharma
Tesaro
Teva Pharmaceuticals
United Therapeutics Corporation
Vanda Pharmaceuticals
Veloxis Pharmaceuticals
Vertex Pharmaceuticals
Wellstat Therapeutics
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
